Skip to main content

Table 2 Plasma or serum lipid profiles in control subjects and patients whose HDL antioxidative activities were measured in apoBd plasma or serum, respectively, with the DCF assay

From: Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins

 

Plasma

Serum

Controls

CHD

High TG

High SAA

Controls

High MPO

Number

59

58

37

28

57

30

M/F, n

30/29

54/4**

25/12

19/9

32/25

15/15

TC, mg/dL

165 ± 26

145 ± 29**

262 ± 178**

163 ± 44

188 ± 38

169 ± 46

HDL-C, mg/dL

59 ± 14

43 ± 13**

34 ± 15**

51 ± 17*

60 ± 15

49 ± 16*

LDL-C, mg/dL

94 ± 19

80 ± 23**

115 ± 68*

89 ± 6

112 ± 35

100 ± 41

TG, mg/dL

74 (63–99)

128 (88–170)**

324 (264–1080)**

115 (92–163)*

97 (70–123)

116 (93–146)

sd LDL-C, mg/dL

16 (14–19)

37 (27–44)**

41 (27–63)**

17 (12–27)

25 (18–32)

23 (19–30)

Apo A-I, mg/dL

158 ± 23

152 ± 34

129 ± 45**

148 ± 48

168 ± 29

149 ± 33

Glucose, mg/dL

110 ± 17

103 ± 31

164 ± 80

110 ± 21

92 ± 15

105 ± 23

Insulin μIU/mL

13.2 ± 13.1

15.1 ± 9.5

19.8 ± 12.1

14.1 ± 7.2

8.3 ± 5.1

22.0 ± 13.5

Hs-CRP, mg/L

1.7 ± 1.9

2.4 ± 4.9

7.9 ± 15.1

5.5 ± 4.4

1.3 ± 1.2

2.7 ± 11.6

HDL distribution

 Preβ-1, %

8 (6–10)

12 (9–15)**

15 (10–19)**

8 (6–11)

5 (4–7)

5 (4–7)

 α-1, %

23 (20–28)

15 (12–19)**

11 (7–17)**

17 (12–21)**

22 (19–25)

20 (16–22)

 α-2, %

44 (42–47)

42 (39–45)*

41 (36–44)*

54 (49–61)**

41 (37–44)

40 (39–43)

 α-3, %

15 (13–16)

18 (16–20)**

17 (13–23)**

11 (9–15)**

13 (12–15)

15 (13–17)

 α-4, %

10 (8–11)

12 (10–14)**

13 (10–16)**

6 (5–9)**

11 (9–12)

12 (10–14)

  1. Data are shown as mean ± SD or median (interquartile range). Differences in values between each group and Controls were tested by Pearson chi-squared test, Student-t test or Mann-Whitney’s U test (*p < 0.05 and **p < 0.01, relative to Controls)